Format

Send to

Choose Destination
J Affect Disord. 2001 May;64(2-3):231-7.

Maintenance desipramine for dysthymia: a placebo-controlled study.

Author information

1
Department of Psychiatry, Weill Medical College of Cornell University, New York, NY 10128, USA. nlmill@cs.com

Abstract

BACKGROUND:

This study examines the efficacy of maintenance pharmacotherapy in dysthymia without concurrent major depression, i.e. 'pure dysthymia'. No published data exist on this topic.

METHODS:

Responders to a 10-week open trial of desipramine (DMI) whose therapeutic response persisted during a 4-month continuation phase were eligible to begin a 2-year placebo-controlled maintenance phase. We analyzed the subgroup with DSM-III-R pure dysthymia (n=27) that entered maintenance. Time to recurrence during maintenance therapy was compared between the two treatment groups.

RESULTS:

Six of 13 patients receiving placebo and none of 14 patients receiving ongoing DMI experienced a recurrence. Risk of recurrence was significantly greater for placebo patients. Five of six placebo recurrences occurred within the first 6 months of maintenance.

LIMITATIONS:

Larger replication studies are needed.

CONCLUSION:

Desipramine was efficacious as a maintenance treatment in patients with pure dysthymia who responded to 7 months of acute and continuation DMI.

PMID:
11313089
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center